PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-184.01%
Negative EBIT growth while AVXL is at 78.93%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-178.81%
Negative operating income growth while AVXL is at 78.93%. Joel Greenblatt would press for urgent turnaround measures.
-184.01%
Negative net income growth while AVXL stands at 112.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-184.12%
Negative EPS growth while AVXL is at 112.50%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-184.12%
Negative diluted EPS growth while AVXL is at 114.81%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-85.28%
Negative OCF growth while AVXL is at 10.22%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-84.23%
Negative FCF growth while AVXL is at 9.74%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-94305.07%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-10645.39%
Negative 5Y OCF/share CAGR while AVXL is at 13.65%. Joel Greenblatt would question the firm’s operational model or cost structure.
-26633.07%
Negative 3Y OCF/share CAGR while AVXL stands at 74.02%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-5092186.63%
Negative 10Y net income/share CAGR while AVXL is at 3042.35%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-138877.64%
Negative 5Y net income/share CAGR while AVXL is 120.58%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-184266.59%
Negative 3Y CAGR while AVXL is 112.31%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-96972.06%
Negative equity/share CAGR over 10 years while AVXL stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-7412.05%
Negative 5Y equity/share growth while AVXL is at 67.73%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-5938.31%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.78%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-763.59%
We have a declining book value while AVXL shows 32.19%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-40.14%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
738.04%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
40.95%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.